Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment,...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q2 CY2026, with sales up 10.2% year on year to $7.80 billio...
Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million).
Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and incre
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on yea...
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate.
Comp
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
President and Chief Executive Officer Eran Ophir described the
Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings reports.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here’s what to expect. Gilead Sciences be...
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.
According to a new report from Intel Market Research, the global Prophylactic HIV Drug Market was valued at USD 3.45 billion in 2025 and is projected to re
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score (CPS ≥10). The European Commission decision on this indication is anticipated later in 2026.
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2026 financial results and provide a business update.
